The Effectiveness of a One-stop Electronic Clinic for Psychological Service (eClinic) in Hong Kong
14 de maio de 2026 atualizado por: New Life Psychiatric Rehabilitation Association
With an increasing need for effective and accessible mental health services, telepsychology can be one promising solution to narrowing the gap between demand and supply.
Our one-stop electronic clinic of psychological service (eClinic) aims to deliver evidence-based treatments to individuals with moderate to severe emotional disorders of various kinds in Hong Kong.
This study examines the cost-effectiveness and cost-efficiency of a hybrid model of telepsychology, in which contact with therapists focuses on facilitating service users' self-learning based on our online interactive modules.
Results will shed light on the benefits of telepsychology to promoting access to mental health services in Hong Kong.
Visão geral do estudo
Status
Concluído
Intervenção / Tratamento
Tipo de estudo
Observacional
Inscrição (Real)
420
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hong Kong
- New Life Psychiatric Rehabilitation Association
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
Aceita Voluntários Saudáveis
Não
Método de amostragem
Amostra Não Probabilística
População do estudo
Individuals aged between 15 and 35 years that are able to speak, read, and write Chinese, and present with moderate to severe depression or anxiety at the time of intake.
Descrição
Inclusion Criteria:
- Screened eligible for and enrolled in the eClinic service
- Age between 15 and 35 years
- Speak, read, and write Chinese
- Present with moderate to severe depression (i.e., Patient Health Questionnaire-9 (PHQ-9) total score ≥ 10) or anxiety (i.e., Generalized Anxiety Disorder-7 (GAD-7) total score ≥ 8)
Exclusion Criteria:
- Present with a history of psychosis in the recent 2 years
- Present with severe risk for self-harm/suicide (i.e., indicated as being at higher risk on the P4 suicidality screener during the service-related screening procedure prior to enrollment in the eClinic service)
- Present with active homicidal ideations (i.e., assessed during the service-related screening procedure prior to enrollment in the eClinic service)
- Demonstrate sub-average intelligence (e.g., based on a history of intellectual disability)
- Concurrently receive other psychological services
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient Health Questionnaire-9 (PHQ-9)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
The PHQ-9 measures the presence of depressive symptoms in the recent two weeks.
The scale measures the nine diagnostic criteria of major depressive disorder on a scale from 0 = not at all to 3 = nearly every day, according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV).
Total score on the PHQ-9 ranges from 0 to 27, with higher scores indicating higher distress.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
|
Generalized Anxiety Disorder-7 (GAD-7)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
The GAD-7 assesses Generalized Anxiety Disorder (GAD) symptoms in the recent two weeks.
It consists of 7 items, each rated on a 4-point Likert scale from 0 = not at all to 3 = nearly every day.
Total score on the GAD-7 ranges from 0 to 21.
A higher GAD-7 score indicates more severe impairment related to GAD symptoms.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Brief Experiential Avoidance Questionnaire (BEAQ)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
The 15-item BEAQ assesses several domains of experiential avoidance.
Items are rated on a 6-point Likert scale of 1 = strong disagree to 6 = strong agree.
Total score of the BEAQ ranges from 15 to 90, with a higher score representing greater experiential avoidance.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
|
Difficulties in Emotion Regulation Scale-16 (DERS-16)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
The DERS-16 assesses level of difficulties with emotion regulation.
Each of the 16 items is rated on a 5-point Likert scale of 1 = almost never to 5 = almost always, with a total score ranges from 16 to 80.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
|
Cognitive Distortions Questionnaire (CD-Quest)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
The CD-Quest is a self-report measure that contains 15 bi-dimensional items that measure the frequency and intensity of 15 cognitive distortions.
For each type of cognitive distortions, participants indicate if it has occurred or not; for any occurrence, individuals rate the frequency and intensity of the cognitive distortion on a 3x3 grid.
Therefore, score on each item ranges from 0 = no (it did not occur) to 5 = occurs almost all the time and with an intensity of more than 70%.
Total score of the CD-Quest ranges from 0 to 75, with a higher score representing a higher frequency and intensity of cognitive distortions.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
|
Cognitive Flexibility Inventory (CFI)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
The CFI is a self-report measure of cognitive flexibility.
20 items of the CFI are rated on a 7-point Likert scale of 1 (strongly disagree) to 7 (strongly agree).
Total score of the CFI ranges from 20 to 140, with higher scores indicating greater cognitive flexibility.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
|
Gratitude Questionnaire-5 (GQ-5)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
The GQ-5 is a self-reported instrument that assesses gratitude.
Five items of the GQ-5 are rated on a 7-point Likert scale from 1 = strongly disagree to 7 = strongly agree.
Total score of the GQ-5 ranges from 5 to 35, with higher scores indicating higher level of gratitude.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
|
Penn State Worry Questionnaire (PSWQ)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
The PSWQ is a 16-item self-report instrument designed to measure the construct of worry.
Each item is rated on a 5-point Likert scale that ranges from 1 = not at all typical of me to 5 = very typical of me.
Five items are reversely scored to obtain a total score ranges from 16 to 80.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
|
Liebowitz Social Anxiety Scale (LSAS)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
The LSAS assesses fear and avoidance related to social anxiety disorder.
The 24-item scale is divided into two broad domains of situations, with 11 items on social anxiety and 13 items on performance fear.
Each of the 24 items is rated on a 4-point Likert scale of 0 = none to 3 = severe for anxiety items or usually for avoidance items.
The total score of LSAS ranges from 0 to 144.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
|
Obsessive-Compulsive Inventory-Revised (OCI-R)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
The OCI-R is an 18-item self-report scale for measuring the severity of obsessive-compulsive symptoms.
Each item is rated on a 5-point Likert scale of 0 = not at all to 4 = extremely.
The OCI-R total score ranges from 0 to 72, with higher scores indicating a greater likelihood of OCD.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
|
Posttraumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
The PCL-5 is a self-report measure of posttraumatic stress disorder (PTSD) symptom severity, based on its diagnostic criteria in Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5).
Each of the 20 items is rated on a 5-point Likert scale of 0 = not at all to 4 = extremely.
The PCL-5 total score ranges from 0 to 80, with higher scores indicating greater PTSD severity.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
|
Insomnia Severity Index (ISI)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
The ISI evaluates the nature, severity, and impact of insomnia.
It consists of 7 items rated on a 5-point Likert scale from 0 = no problem to 4 = very severe problem, with a total score ranging from 0 to 28.
Higher scores on the ISI indicate more severe insomnia.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
|
Short Health Anxiety Inventory (SHAI)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
The SHAI is an 18-item self-report measure that assesses an individual's concern about possibly having health illnesses of different kinds, and the catastrophic thinking about having the illnesses.
Total score of the SHAI ranges from 0 to 54, where higher scores indicate greater health anxiety.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 1-, 2-, 3-, 6-, and 12-month follow-up
|
|
Work and Social Adjustment Scale (WSAS)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
The WSAS is a 5-item scale that measures self-report severity of impairment across five domains of functioning.
Each item is rated on a 9-point Likert scale of 0 = not at all to 8 = very severely.
Total score of the WSAS ranges from 0 to 40, where higher scores indicate greater functional impairment.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
|
Rosenberg Self-Esteem Scale (RSES)
Prazo: Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
The RSE has 10 items that assess self-esteem, each rated on a 4-point Likert scale of 1 = strongly agree to 4 = strongly disagree.
Total score of the RSE ranges from 0 to 30, with lower scores suggesting lower self-esteem.
|
Baseline (week 0), post-intensive (week 5; after completion of core modules), posttreatment (week 14; completion of the intervention), and 3- and 12-month follow-up
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
28 de dezembro de 2022
Conclusão Primária (Real)
31 de outubro de 2025
Conclusão do estudo (Real)
31 de outubro de 2025
Datas de inscrição no estudo
Enviado pela primeira vez
8 de maio de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
14 de maio de 2026
Primeira postagem (Real)
20 de maio de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
20 de maio de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
14 de maio de 2026
Última verificação
1 de abril de 2026
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2022.106
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .